TIO Bioventures

Treadwell Therapeutics is a clinical-stage oncology company developing medicines to address unmet cancer needs. Based in New York, it maintains an internally developed pipeline that includes CFI-400945, a PLK4 kinase inhibitor; CFI-402257, a TTK inhibitor; and CFI-402411, an oral immunomodulatory HPK1 kinase inhibitor. The firm pursues cancer therapies through small molecules and next-generation biologics, supported by a platform designed to exploit cancer cell vulnerabilities and enable discovery and development across early to late-stage programs, including preclinical TCR-based autologous cell therapy programs. Founded by leading scientists, the company focuses on delivering targeted treatments to improve patient outcomes.

TCRyption is a preclinical company focused on the development of novel approaches to TCR based cellular therapy for cancer and other indications. TCRyption seeks to develop a pipeline of product candidates that can treat cancer type and patient populations that are underserved by current approaches.